The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Cancer Therapy

• Publication date

  2014-09-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4236/JCT.2014.510099
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Recurrent, Refractory or Progressive Primary Brain Tumors—Final Report (Protocol BT-22)

  2014cited by this paper
• Recurrent Glioblastoma Multiforme—A Strategy for Long-Term Survival

  2014cited by this paper
• A Phase II Study of Antineoplastons A10 and AS2-1 in Children with High-Grade Glioma. Final Report (Protocol BT-06), and Review of Recent Trials

  2014cited by this paper
• A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Recurrent Glioblastoma Multiforme: Final Report (Protocol BT-21)

  2014cited by this paper
• Comment to the paper: The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma

  2014cited by this paper
• ERKs in cancer: friends or foes?

  2014cited by this paper
• Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.

  2013cited by this paper
• CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

  2013cited by this paper
• Key concepts in glioblastoma therapy

  2012cited by this paper
• Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Molecular Pathways: Regulation of Metabolism by RB

  2012cited by this paper
• Molecular and Cellular Pathobiology The Metabolomic Signature of Malignant Glioma Re fl ects Accelerated Anabolic Metabolism

  2012cited by this paper
• Phenylacetylglutaminate and Phenylacetate in Combination Upregulate VDUP1, Cause Cell Cycle Blockade and Apoptosis in U87 Glioblastoma Cells

  2012influential reference
• Clinical trials in the era of personalized oncology

  2011cited by this paper
• Pathway inhibition: emerging molecular targets for treating glioblastoma.

  2011cited by this paper
• A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas

  2011cited by this paper
• Clinical and Experimental Applications of Sodium Phenylbutyrate

  2011cited by this paper
• Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer

  2010cited by this paper
• Glutamine addiction: a new therapeutic target in cancer.

  2010cited by this paper
• c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism

  2009cited by this paper
• MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities

  2009cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2009cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells

  2007cited by this paper
• Central nervous system tumors.

  2007cited by this paper
• Treatments for Astrocytic Tumors in Children

  2006cited by this paper
• Treatments for astrocytic tumors in children: current and emerging strategies.

  2006cited by this paper
• What have animal models taught us about the p53 pathway?

  2005cited by this paper
• Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells.

  2005cited by this paper
• The tor pathway: a target for cancer therapy

  2004cited by this paper
• Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

  2004cited by this paper
• G1 cell-cycle control and cancer

  2004cited by this paper
• Targeting apoptosis pathways in cancer therapy.

  2004cited by this paper
• The Present State of Antineoplaston Research (1)

  2004cited by this paper
• Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors

  2004cited by this paper
• RAS oncogenes: the first 30 years

  2003cited by this paper
• VDUP1 upregulated by TGF-β1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression

  2003cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• c-MYC: more than just a matter of life and death

  2002cited by this paper
• Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo

  2001influential reference
• Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.

  2001influential reference
• Identification of Thioredoxin-binding Protein-2/Vitamin D3 Up-regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression*

  1999cited by this paper
• Identification and classification of p53-regulated genes.

  1999cited by this paper
• Targeted therapy for brain tumours

  1998cited by this paper
• Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis.

  1997cited by this paper
• p53, the Cellular Gatekeeper Review for Growth and Division

  1997cited by this paper
• Constitutive Protection of E2F Recognition Sequences in the Human Thymidine Kinase Promoter during Cell Cycle Progression*

  1997cited by this paper
• Potential of Antineoplastons in Diseases of Old Age

  1995cited by this paper
• G1/S-regulated E2F-containing protein complexes bind to the mouse thymidine kinase gene promoter.

  1994cited by this paper
• WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

  1994cited by this paper
• Primary brain tumors: review of etiology, diagnosis and treatment.

  1994cited by this paper
• E2F mediates dihydrofolate reductase promoter activation and multiprotein complex formation in human cytomegalovirus infection

  1992cited by this paper
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

  1990cited by this paper
• Antineoplastons: history of the research (I).

  1986influential reference
• Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis.

  1984cited by this paper
• Biological active peptides in human urine: III. Inhibitors of the growth of human leukemia, osteosarcoma, and HeLa cells.

  1976cited by this paper
• Antineoplastons: biochemical defense against cancer.

  1976cited by this paper
• Biologically active peptides in human urine: II. Effect on intestinal smooth muscle and heart.

  1974cited by this paper
• Biologically active peptides in human urine. I. Isolation of a group of medium-sized peptides.

  1973cited by this paper
• Investigations on unknown ninhydrin-reacting substances in human blood serum. I. Attempts at identification of three such substances

  1969cited by this paper

• “Cytokine-Mediated tumor sensitization: mechanistic frameworks and therapeutic opportunities in cancer Immunotherapy”

  2026cites this paper
• Recurrent Pilocytic Astrocytoma: Treatment with Antineoplastons, Complete Response, and > 27 Years Overall Survival

  2024cites this paper
• Recurrent Desmoplastic Infantile Ganglioglioma Treated with Antineoplastons: Partial Response and Overall Survival of > 11.8 Years in a Ten-Month-Old Female

  2024cites this paper
• A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways, clinical trials, and challenges

  2024cites this paper
• Inoperable Optic Pathway Glioma: A Seven-Year-Old Male with >35 Years Overall Survival Following Treatment with Antineoplastons

  2023cites this paper
• Recurrent/Persistent Glioblastoma: Complete Response and 24 Years Disease-free Survival in a 45-Year-Old Female Treated with Antineoplastons (Successful Treatment of Glioblastoma with Antineoplastons)

  2022cites this paper
• Newly Diagnosed Glioblastoma: Partial Response and > 27 Years Overall Survival in 37-Year-Old Male Treated with Antineoplastons (Treatment of Glioblastoma with Antineoplastons)

  2022cites this paper
• Long-Term Survival (27.7 Years) Following IV Antineoplaston Therapy (ANP) in a 36-Year-Old Female with a Progressive Diffuse Intrinsic Pontine Glioma (DIPG)

  2021cites this paper
• Understanding the Biological Activities of Vitamin D in Type 1 Neurofibromatosis: New Insights into Disease Pathogenesis and Therapeutic Design

  2020cites this paper
• Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy

  2019cites this paper
• A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Low-Grade Astrocytomas—Final Report (Protocol BT-13)

  2016cites this paper
• A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Newly-Diagnosed Anaplastic Astrocytoma-Final Report (Protocol BT-08)

  2015cites this paper
• A Phase II Study of Antineoplastons A 10 and AS 2-1 Injections in Adult Patients With Recurrent Anaplastic Astrocytoma — Final report ( Protocol BT15 )

  2015cites this paper
• A Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Gliomas. The Report on Non-Diffuse Intrinsic Pontine Glioma (Protocol BT-11)

  2015cites this paper
• A Case of Sustained Objective Response of Recurrent/Progressive Diffuse Intrinsic Pontine Glioma with Phenylbutyrate and Targeted Agents

  2015cites this paper
• Comprehensive Genomic Profiling of Recurrent Classic Glioblastoma in a Patient Surviving Eleven Years Following Antineoplaston Therapy

  2015influential citation
• A Phase II Study of Antineoplastons A10 and AS2-1 Injections in Adult Patients With Recurrent Anaplastic Astrocytoma—Final report (Protocol BT-15)

  2015cites this paper
• Long-Term Survival Over 21 Years and Pathologically Confirmed Complete Response in Pediatric Anaplastic Astrocytoma: A Case Report

  2015cites this paper
• Recurrent Glioblastoma Multiforme—A Strategy for Long-Term Survival

  2014cites this paper
• Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival

  2014cites this paper
• Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancer—A Potential Strategy for Improved Survival

  2014cites this paper
• Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Advanced Malignant Mesothelioma: A Strategy for Improved Survival

  2014cites this paper
• A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Recurrent Glioblastoma Multiforme: Final Report (Protocol BT-21)

  2014cites this paper
• Preliminary Findings on the Use of Targeted Therapy with Pazopanib and Other Agents in Combination with Sodium Phenylbutyrate in the Treatment of Glioblastoma Multiforme

  2014cites this paper